Antiblastic  ||| S:0 E:12 ||| JJ
treatment ||| S:12 E:21 ||| NN
,  ||| S:21 E:23 ||| ,
for  ||| S:23 E:27 ||| IN
solid  ||| S:27 E:33 ||| JJ
tumors ||| S:33 E:39 ||| NNS
,  ||| S:39 E:41 ||| ,
during  ||| S:41 E:48 ||| IN
pregnancy ||| S:48 E:57 ||| NN
:  ||| S:57 E:59 ||| :
a  ||| S:59 E:61 ||| DT
crucial  ||| S:61 E:69 ||| JJ
decision  ||| S:69 E:78 ||| NN
Cancer  ||| S:78 E:85 ||| NNP
is  ||| S:85 E:88 ||| VBZ
the  ||| S:88 E:92 ||| DT
second  ||| S:92 E:99 ||| JJ
leading  ||| S:99 E:107 ||| JJ
cause  ||| S:107 E:113 ||| NN
of  ||| S:113 E:116 ||| IN
death  ||| S:116 E:122 ||| NN
during  ||| S:122 E:129 ||| IN
the  ||| S:129 E:133 ||| DT
reproductive  ||| S:133 E:146 ||| JJ
years  ||| S:146 E:152 ||| NNS
complicating  ||| S:152 E:165 ||| VBN
between  ||| S:165 E:173 ||| IN
0.02  ||| S:173 E:178 ||| CD
percent  ||| S:178 E:186 ||| NN
and  ||| S:186 E:190 ||| CC
0.1  ||| S:190 E:194 ||| CD
percent  ||| S:194 E:202 ||| NN
of  ||| S:202 E:205 ||| IN
pregnancies ||| S:205 E:216 ||| NN
.  ||| S:216 E:218 ||| .
The  ||| S:218 E:222 ||| DT
incidence  ||| S:222 E:232 ||| NN
is  ||| S:232 E:235 ||| VBZ
expected  ||| S:235 E:244 ||| VBN
to  ||| S:244 E:247 ||| TO
rise  ||| S:247 E:252 ||| VB
with  ||| S:252 E:257 ||| IN
the  ||| S:257 E:261 ||| DT
increase  ||| S:261 E:270 ||| NN
in  ||| S:270 E:273 ||| IN
age  ||| S:273 E:277 ||| NN
of  ||| S:277 E:280 ||| IN
childbearing ||| S:280 E:292 ||| NN
.  ||| S:292 E:294 ||| .
The  ||| S:294 E:298 ||| DT
most  ||| S:298 E:303 ||| RBS
common  ||| S:303 E:310 ||| JJ
types  ||| S:310 E:316 ||| NNS
of  ||| S:316 E:319 ||| IN
pregnancy-associated  ||| S:319 E:340 ||| JJ
cancers  ||| S:340 E:348 ||| NNS
are ||| S:348 E:351 ||| VBP
:  ||| S:351 E:353 ||| :
cervical  ||| S:353 E:362 ||| JJ
cancer ||| S:362 E:368 ||| NN
,  ||| S:368 E:370 ||| ,
breast  ||| S:370 E:377 ||| JJ
cancer ||| S:377 E:383 ||| NN
,  ||| S:383 E:385 ||| ,
malignant  ||| S:385 E:395 ||| JJ
melanoma ||| S:395 E:403 ||| NN
,  ||| S:403 E:405 ||| ,
Hodgkin ||| S:405 E:412 ||| NNP
's  ||| S:412 E:415 ||| POS
lymphoma ||| S:415 E:423 ||| NN
,  ||| S:423 E:425 ||| ,
non-Hodgkin ||| S:425 E:436 ||| NNP
's  ||| S:436 E:439 ||| POS
lymphoma  ||| S:439 E:448 ||| NN
and  ||| S:448 E:452 ||| CC
ovarian  ||| S:452 E:460 ||| JJ
cancer ||| S:460 E:466 ||| NN
.  ||| S:466 E:468 ||| .
The  ||| S:468 E:472 ||| DT
relatively  ||| S:472 E:483 ||| RB
rare  ||| S:483 E:488 ||| JJ
occurrence  ||| S:488 E:499 ||| NN
of  ||| S:499 E:502 ||| IN
pregnancy-associated  ||| S:502 E:523 ||| JJ
cancer  ||| S:523 E:530 ||| NN
precludes  ||| S:530 E:540 ||| VBZ
conducting  ||| S:540 E:551 ||| VBG
large ||| S:551 E:556 ||| JJ
,  ||| S:556 E:558 ||| ,
prospective  ||| S:558 E:570 ||| JJ
studies  ||| S:570 E:578 ||| NNS
to  ||| S:578 E:581 ||| TO
examine  ||| S:581 E:589 ||| VB
diagnostic ||| S:589 E:599 ||| JJ
,  ||| S:599 E:601 ||| ,
management  ||| S:601 E:612 ||| NN
and  ||| S:612 E:616 ||| CC
outcome  ||| S:616 E:624 ||| NN
issues ||| S:624 E:630 ||| NNS
.  ||| S:630 E:632 ||| .
The  ||| S:632 E:636 ||| DT
treatment  ||| S:636 E:646 ||| NN
of  ||| S:646 E:649 ||| IN
pregnancy-associated  ||| S:649 E:670 ||| JJ
cancer  ||| S:670 E:677 ||| NN
is  ||| S:677 E:680 ||| VBZ
complex  ||| S:680 E:688 ||| JJ
since  ||| S:688 E:694 ||| IN
it  ||| S:694 E:697 ||| PRP
may  ||| S:697 E:701 ||| MD
be  ||| S:701 E:704 ||| VB
associated  ||| S:704 E:715 ||| VBN
with  ||| S:715 E:720 ||| IN
adverse  ||| S:720 E:728 ||| JJ
fatal  ||| S:728 E:734 ||| JJ
effects ||| S:734 E:741 ||| NNS
.  ||| S:741 E:743 ||| .
In  ||| S:743 E:746 ||| IN
pregnant  ||| S:746 E:755 ||| JJ
patients  ||| S:755 E:764 ||| NNS
diagnosed  ||| S:764 E:774 ||| VBN
with  ||| S:774 E:779 ||| IN
cancer  ||| S:779 E:786 ||| NN
during  ||| S:786 E:793 ||| IN
the  ||| S:793 E:797 ||| DT
first  ||| S:797 E:803 ||| JJ
trimester ||| S:803 E:812 ||| NN
,  ||| S:812 E:814 ||| ,
treatment  ||| S:814 E:824 ||| NN
with  ||| S:824 E:829 ||| IN
multidrug  ||| S:829 E:839 ||| JJ
anti-cancer  ||| S:839 E:851 ||| JJ
chemotherapy  ||| S:851 E:864 ||| NN
is  ||| S:864 E:867 ||| VBZ
associated  ||| S:867 E:878 ||| VBN
with  ||| S:878 E:883 ||| IN
an  ||| S:883 E:886 ||| DT
increased  ||| S:886 E:896 ||| JJ
risk  ||| S:896 E:901 ||| NN
of  ||| S:901 E:904 ||| IN
congenital  ||| S:904 E:915 ||| JJ
malformations ||| S:915 E:928 ||| NN
,  ||| S:928 E:930 ||| ,
spontaneous  ||| S:930 E:942 ||| JJ
abortions  ||| S:942 E:952 ||| NNS
or  ||| S:952 E:955 ||| CC
fetal  ||| S:955 E:961 ||| JJ
death ||| S:961 E:966 ||| NN
,  ||| S:966 E:968 ||| ,
and  ||| S:968 E:972 ||| CC
therefore ||| S:972 E:981 ||| RB
,  ||| S:981 E:983 ||| ,
should  ||| S:983 E:990 ||| MD
follow  ||| S:990 E:997 ||| VB
a  ||| S:997 E:999 ||| DT
strong  ||| S:999 E:1006 ||| JJ
recommendation  ||| S:1006 E:1021 ||| NN
for  ||| S:1021 E:1025 ||| IN
pregnancy  ||| S:1025 E:1035 ||| NN
termination ||| S:1035 E:1046 ||| NN
.  ||| S:1046 E:1048 ||| .
Second  ||| S:1048 E:1055 ||| JJ
and  ||| S:1055 E:1059 ||| CC
third  ||| S:1059 E:1065 ||| JJ
trimester  ||| S:1065 E:1075 ||| JJ
exposure  ||| S:1075 E:1084 ||| NN
is  ||| S:1084 E:1087 ||| VBZ
not  ||| S:1087 E:1091 ||| RB
associated  ||| S:1091 E:1102 ||| VBN
with  ||| S:1102 E:1107 ||| IN
teratogenic  ||| S:1107 E:1119 ||| JJ
effect  ||| S:1119 E:1126 ||| NN
but  ||| S:1126 E:1130 ||| CC
increases  ||| S:1130 E:1140 ||| VBZ
the  ||| S:1140 E:1144 ||| DT
risk  ||| S:1144 E:1149 ||| NN
of  ||| S:1149 E:1152 ||| IN
intrauterine  ||| S:1152 E:1165 ||| JJ
growth  ||| S:1165 E:1172 ||| NN
retardation  ||| S:1172 E:1184 ||| NN
and  ||| S:1184 E:1188 ||| CC
low  ||| S:1188 E:1192 ||| JJ
birth  ||| S:1192 E:1198 ||| NN
weight ||| S:1198 E:1204 ||| NN
.  ||| S:1204 E:1206 ||| .
There  ||| S:1206 E:1212 ||| EX
are  ||| S:1212 E:1216 ||| VBP
no  ||| S:1216 E:1219 ||| DT
sufficient  ||| S:1219 E:1230 ||| JJ
data  ||| S:1230 E:1235 ||| NNS
regarding  ||| S:1235 E:1245 ||| VBG
the  ||| S:1245 E:1249 ||| DT
teratogenicity  ||| S:1249 E:1264 ||| NN
of  ||| S:1264 E:1267 ||| IN
most  ||| S:1267 E:1272 ||| RBS
cytotoxic  ||| S:1272 E:1282 ||| JJ
drugs ||| S:1282 E:1287 ||| NNS
.  ||| S:1287 E:1289 ||| .
Almost  ||| S:1289 E:1296 ||| RB
all  ||| S:1296 E:1300 ||| DT
chemotherapeutic  ||| S:1300 E:1317 ||| JJ
agents  ||| S:1317 E:1324 ||| NNS
were  ||| S:1324 E:1329 ||| VBD
found  ||| S:1329 E:1335 ||| VBN
to  ||| S:1335 E:1338 ||| TO
be  ||| S:1338 E:1341 ||| VB
teratogenic  ||| S:1341 E:1353 ||| VBN
in  ||| S:1353 E:1356 ||| IN
animals  ||| S:1356 E:1364 ||| NNS
and  ||| S:1364 E:1368 ||| CC
for  ||| S:1368 E:1372 ||| IN
some  ||| S:1372 E:1377 ||| DT
drugs  ||| S:1377 E:1383 ||| NNS
only  ||| S:1383 E:1388 ||| RB
experimental  ||| S:1388 E:1401 ||| JJ
data  ||| S:1401 E:1406 ||| NNS
exist ||| S:1406 E:1411 ||| VBP
.  ||| S:1411 E:1413 ||| .
Moreover ||| S:1413 E:1421 ||| RB
,  ||| S:1421 E:1423 ||| ,
no  ||| S:1423 E:1426 ||| DT
pharmacokinetic  ||| S:1426 E:1442 ||| JJ
studies  ||| S:1442 E:1450 ||| NNS
have  ||| S:1450 E:1455 ||| VBP
been  ||| S:1455 E:1460 ||| VBN
conducted  ||| S:1460 E:1470 ||| VBN
in  ||| S:1470 E:1473 ||| IN
pregnant  ||| S:1473 E:1482 ||| JJ
women  ||| S:1482 E:1488 ||| NNS
receiving  ||| S:1488 E:1498 ||| VBG
chemotherapy  ||| S:1498 E:1511 ||| NN
in  ||| S:1511 E:1514 ||| IN
order  ||| S:1514 E:1520 ||| NN
to  ||| S:1520 E:1523 ||| TO
understand  ||| S:1523 E:1534 ||| VB
whether  ||| S:1534 E:1542 ||| IN
pregnant  ||| S:1542 E:1551 ||| JJ
women  ||| S:1551 E:1557 ||| NNS
should  ||| S:1557 E:1564 ||| MD
be  ||| S:1564 E:1567 ||| VB
treated  ||| S:1567 E:1575 ||| VBN
with  ||| S:1575 E:1580 ||| IN
different  ||| S:1580 E:1590 ||| JJ
doses  ||| S:1590 E:1596 ||| NNS
of  ||| S:1596 E:1599 ||| IN
chemotherapy ||| S:1599 E:1611 ||| NN
.  ||| S:1611 E:1613 ||| .
This  ||| S:1613 E:1618 ||| DT
article  ||| S:1618 E:1626 ||| NN
reviews  ||| S:1626 E:1634 ||| VBZ
the  ||| S:1634 E:1638 ||| DT
available  ||| S:1638 E:1648 ||| JJ
data  ||| S:1648 E:1653 ||| NNS
regarding  ||| S:1653 E:1663 ||| VBG
the  ||| S:1663 E:1667 ||| DT
different  ||| S:1667 E:1677 ||| JJ
aspects  ||| S:1677 E:1685 ||| NNS
of  ||| S:1685 E:1688 ||| IN
the  ||| S:1688 E:1692 ||| DT
treatment  ||| S:1692 E:1702 ||| NN
of  ||| S:1702 E:1705 ||| IN
cancer  ||| S:1705 E:1712 ||| NN
during  ||| S:1712 E:1719 ||| IN
pregnancy ||| S:1719 E:1728 ||| NN
.  ||| S:1728 E:1730 ||| .
